Targeted Agents in Treatment of Neuroendocrine Tumors of Pancreas

Highlights from the “ASCO Annual Meeting”. Chicago, IL, USA. May 30 - June 3, 2014.

Ilias N Karampelas1, Kostas N Syrigos2, Muhammad Wasif Saif3

1Oncology Department, Athens Medical Group, Athens, Greece.
2Oncology Unit, Third Department of Medicine, University of Athens. Athens, Greece.
3Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine. Boston, MA, USA

ABSTRACT

Neuroendocrine tumors (NETs) of the pancreas are uncommon neoplasms that arise from the pancreatic islet cells. Surgical resections are being tested, as well as multiple chemotherapy agents. Current treatment options for nonresectable disease include somatostatin analogs and chemotherapy. New therapies focus on specific molecular targets such as sunitinib, angiogenesis inhibitor, that target vascular endothelial growth factor receptor (VEGFR) and other growth factor receptors and everolimus, an inhibitor of the mammalian target of rapamycin. Functionally based medical therapies for NET include somatostatin analogs to control symptoms. The 2014 annual meeting of American Society of Clinical Oncology (ASCO) brought us new insights into the management of pancreatic neuroendocrine tumors. The focus of this review will serve to highlight specific Abstracts (#e15160 and #e15161), that shed light on new therapeutic options that help target the unique pathways of this malignancies.

What Did We Know Before ASCO 2014?

Neuroendocrine tumors (NETs) are uncommon, with an estimated incidence of 2.5-5 per 100,000 people per year and prevalence of 35 per 100,000 [1]. Survival rates vary by primary site and are higher in patients with well-differentiated tumors, and with locoregional versus distant disease [2]. Most of the tumors are insulinomas, glucagonomas, gastrinomas, somatostatinomas, VIPomas, pancreatic polypeptidomas and cholecystokininomas. Based on histology they are divided in three categories, well differentiated/low grade, well differentiated/intermediate grade and poorly differentiated/high grade. Although, resection of localized disease can prove curative, metastases are already present, in most of the cases, in the time of the diagnosis, so the tumor is unresectable just from the beginning [3]. For patients with well differentiated or moderately differentiated pancreatic NETs (pNETs) with distant metastatic disease, the median survival time is 24 months [3]. In April 2011 the FDA approved molecularly targeted agents, everolimus, tyrosine kinases, mammalian target of rapamycin (mTOR), and vascular endothelial growth factor receptors (VEGFR) have been used with success in the treatment of gastroenteropancreatic NET. This approval was based on RADIANT-3 study, which was first reported at the ASCO GI Symposium in January 2011 [4]. A phase III trial looked at sunitinib in unresectable pNET and found an improvement in progression free survival from 5.5 to 11.4 months when compared to placebo [5]. Concerning to somatostatin analogs, can be used to control symptoms associated with carcinoid syndrome [6]. Short and long acting octreotide remains the most widely used somatostatin analog. In 2009, the PROMID trial demonstrated that the use of octreotide improved median time to progression to 14.3 months [7]. In 2013, follow up data of PROMID trial improve an increasing overall survival [8]. In 2013, Bajetta et al. presented a phase II data suggesting that the addition of everolimus to octreotide therapy benefits progression free survival (16.3 months) in the first line setting when treating advanced gastroenteropancreatic NET [9].

What We Learn at ASCO 2014?

This paper summarizes the recent work presented at the 2014 ASCO Annual Meeting, regarding in targeted agents in treatment of neuroendocrine tumors of pancreas. The purpose of this paper is to present the data of the two presented abstracts.

Updated Overall Survival and Time to Progression Results in Nets Treated with Everolimus Combination with Octreotide LAR as First-Line Treatment.

Emilio Bajetta et al. performed an analysis to evaluate the objective response rate (ORR), a further prolongation of the median time to progression (TTP) and the overall survival (OS), suggesting a possible long term benefit of the combination of everolimus with octreotide LAR as first-line treatment (Abstract #15160 [10]) (Table 1). A total of 50 patients with advanced well differentiated, previously untreated NETs of a gastroenteropancreatic
Median Progression free survival: 18 months

Phase II
Sunitinib plus/ or Everolimus
Target Dose: 30mg Octreotide monthly + 10mg Somatostatin analogs mTOR Inhibitor

Median Progression free survival: 17.8 months
50 Patients with advanced NET
Beneficial synergic effect
n of 18 (14-23)
Trial
Median overall survival: has not been reached
Median Progression free survival: 18 months
7 patients with pNET Ki67>15

Surgical resection remains the gold standard of treatment for patients with localized disease. However, most NETs are unresectable at diagnosis or progress after local treatment and there have been relatively few treatments options. Traditional systemic treatment options for pancreatic NETs include somatostatin analogs or cytotoxic chemotherapy. Patients with pNETs have been reported to cause response 23%-70%. [12]. New treatments have come up recently. Everolimus, an mTOR inhibitor which inhibits cell growth, proliferation, and angiogenesis, and has been shown to prolong progression free survival compared to placebo. Sunitinib is a multi-kinase inhibitor effective in NET through inhibition of VEGF [13]. Both agents provide clinical benefit for patients with NETs. Somatostatin analogs have been shown to be efficacious in the treatment of gastroenteropancreatic NET. Previously presented phase II study data shows that the combination of everolimus and octreotide LAR in the first line treatment for advanced NETs is an active and a safe solution [9]. It was necessary to know if there is a further prolongation of the median time to progression (TTP), suggesting a possible long term benefit of this combination. In Abstract #e15160 [10], Emilio Bajetto et al. demonstrated that there is a prolonged benefit of everolimus in combination with long acting somatostatin analogs in NETs. Interestingly, this trial showed that everolimus could be combined with somatostatin analogs without affecting the safety profile of either everolimus or somatostatin analogs.

Tumors with a high histologic grade, a mitotic count >20 per 10 high-powered fields (HPF), or a Ki-67 proliferation index of >20% represent aggressive neuroendocrine carcinomas that have a different natural history and response to treatment compared to low-grade, well-differentiated tumors. In Abstract #e15161 [11], Geboes et al. reported that there was benefit of sunitinib and/or everolimus in durable disease control in patients with a well differentiated NET of the pancreas. The beneficial synergistic effect, on durable disease, when combining everolimus with sunitinib, presents us promising possibilities in treating our patients with pancreatic NETs. This opens the door to using mTOR inhibitors with other molecularly targeted agents.

Table 1. Agents in unresectable NETs.

<table>
<thead>
<tr>
<th>Chemo-therapeutic Agent</th>
<th>Everolimus with octreotide-LAR</th>
<th>Sunitinib plus everolimus</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Target</strong></td>
<td>Somatostatin analogs mTOR Inhibitor</td>
<td>Sunitinib plus/ or Everolimus</td>
</tr>
<tr>
<td><strong>Study Design</strong></td>
<td>Phase II</td>
<td>Trial</td>
</tr>
<tr>
<td><strong>Population</strong></td>
<td>50 Patients with advanced NET</td>
<td>7 patients with pNET Ki67&gt;15</td>
</tr>
<tr>
<td><strong>Response</strong></td>
<td>Median Progression free survival: 17.8 months</td>
<td>Median Progression free survival: 18 months</td>
</tr>
<tr>
<td><strong>Comment</strong></td>
<td>Target Dose: 30mg Octreotide monthly + 10mg Everolimus</td>
<td>Beneficial synergic effect</td>
</tr>
</tbody>
</table>

Durable Disease Control with Sunitinib and Everolimus in Well-Differentiated Neuroendocrine Tumors of the Pancreas with a High Ki67 Index

Karen Paula Geboes et al. presented the results of a study, analyzing patients with well-differentiated neuroendocrine tumors of the pancreas, with a high ki67 index, who received sunitinib and everolimus in order to control durable disease (Abstract #15161 [11]) (Table 1). Furthermore, patients had an uptake of lesions on octreoscan and/or gallium68 dotatoc. A total of 7 patients with advanced well differentiated NET of the pancreas, with median ki67 index 23 (IQR: 16–38%), were studied. The disease was controlled for a median of 18 (14-23) months on sunitinib and/or everolimus. The longer duration of disease control in more patients warrants further investigation.

Discussion

Surgical resection remains the gold standard of treatment for patients with localized disease. However, most NETs are unresectable at diagnosis or progress after local treatment and there have been relatively few treatments options. Traditional systemic treatment options for pancreatic NETs include somatostatin analogs or cytotoxic chemotherapy. Patients with pNETs have been reported to cause response 23%-70%. [12]. New treatments have come up recently. Everolimus, an mTOR inhibitor which inhibits cell growth, proliferation, and angiogenesis, and has been shown to prolong progression free survival compared to placebo. Sunitinib is a multi-kinase inhibitor effective in NET through inhibition of VEGF [13]. Both agents provide clinical benefit for patients with NETs. Somatostatin analogs have been shown to be efficacious in the treatment of gastroenteropancreatic NET. Previously presented phase II study data shows that the combination of everolimus and octreotide LAR in the first line treatment for advanced NETs is an active and a safe solution [9]. It was necessary to know if there is a further prolongation of the median time to progression (TTP), suggesting a possible long term benefit of this combination. In Abstract #e15160 [10], Emilio Bajetto et al. demonstrated that there is a prolonged benefit of everolimus in combination with long acting somatostatin analogs in NETs. Interestingly, this trial showed that everolimus could be combined with somatostatin analogs without affecting the safety profile of either everolimus or somatostatin analogs.

Tumors with a high histologic grade, a mitotic count >20 per 10 high-powered fields (HPF), or a Ki-67 proliferation index of >20% represent aggressive neuroendocrine carcinomas that have a different natural history and response to treatment compared to low-grade, well-differentiated tumors. In Abstract #e15161 [11], Geboes et al. reported that there was benefit of sunitinib and/or everolimus in durable disease control in patients with a well differentiated NET of the pancreas. The beneficial synergistic effect, on durable disease, when combining everolimus with sunitinib, presents us promising possibilities in treating our patients with pancreatic NETs. This opens the door to using mTOR inhibitors with other molecularly targeted agents.

Conflict of Interest

Authors declare to have no such conflict of interest.

References


